- Home
- MAX vs PHAR Comparison
MAX vs PHAR Comparison
Compare MAX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PHAR
- Stock Information
- Founded
- MAX 2014
- PHAR 1988
- Country
- MAX United States
- PHAR Netherlands
- Employees
- MAX N/A
- PHAR N/A
- Industry
- MAX Industrial Machinery/Components
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PHAR Health Care
- Exchange
- MAX Nasdaq
- PHAR Nasdaq
- Market Cap
- MAX 582.4M
- PHAR 731.1M
- IPO Year
- MAX 2020
- PHAR N/A
- Fundamental
- Price
- MAX $10.46
- PHAR $10.31
- Analyst Decision
- MAX Strong Buy
- PHAR Strong Buy
- Analyst Count
- MAX 6
- PHAR 3
- Target Price
- MAX $17.92
- PHAR $30.00
- AVG Volume (30 Days)
- MAX 419.3K
- PHAR 3.6K
- Earning Date
- MAX 07-30-2025
- PHAR 07-31-2025
- Dividend Yield
- MAX N/A
- PHAR N/A
- EPS Growth
- MAX N/A
- PHAR N/A
- EPS
- MAX 0.28
- PHAR N/A
- Revenue
- MAX $1,002,364,000.00
- PHAR $320,708,000.00
- Revenue This Year
- MAX $24.09
- PHAR $13.31
- Revenue Next Year
- MAX $11.18
- PHAR $7.68
- P/E Ratio
- MAX $37.31
- PHAR N/A
- Revenue Growth
- MAX 148.62
- PHAR 24.13
- 52 Week Low
- MAX $7.33
- PHAR $6.65
- 52 Week High
- MAX $20.91
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- MAX 45.90
- PHAR 43.60
- Support Level
- MAX $10.05
- PHAR $9.99
- Resistance Level
- MAX $11.14
- PHAR $10.49
- Average True Range (ATR)
- MAX 0.37
- PHAR 0.34
- MACD
- MAX -0.07
- PHAR -0.14
- Stochastic Oscillator
- MAX 26.43
- PHAR 7.45
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.